(Q37011986)

17 August 2017

1 reference

title

Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis (English)

1 reference

17 August 2017

3

Caroline M Perry

1 reference

17 August 2017

Paul L McCormack

1

1 reference

17 August 2017

Dean M Robinson

series ordinal

2

1 reference

17 August 2017

publication date

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

67

1 reference

17 August 2017

issue

17

1 reference

17 August 2017

page(s)

2635-2642

1 reference

Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study

17 August 2017

cites work

1 reference

12 December 2020

A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.

1 reference

12 December 2020

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

1 reference

12 December 2020

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis

1 reference

12 December 2020

MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials

1 reference

12 December 2020

Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis

1 reference

12 December 2020

Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis

1 reference

12 December 2020

Histologic and colonoscopic assessment of disease extension in ulcerative colitis

1 reference

12 December 2020

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

1 reference

12 December 2020

5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis

1 reference

12 December 2020

Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease

1 reference

12 December 2020

Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis

1 reference

12 December 2020

Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease

1 reference

12 December 2020

A practical guide to the management of distal ulcerative colitis

1 reference

12 December 2020

10.2165/00003495-200767170-00010

Identifiers

DOI

1 reference

Dimensions Publication ID

17 August 2017

1015530562

0 references

1 reference